Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Sun Pharmaceutical Industries has appointed Aalok Shanghvi as its Chief Operating Officer (COO). The company announced the designation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shanghvi has been with Sun Pharma since 2006, holding various roles across marketing, research and development (R&D), project management, procurement, and communications. In 2014, he became Head of Emerging Markets, overseeing business operations in 80 countries, including Africa, the Middle East, Asia-Pacific, Eastern Europe, the Commonwealth of Independent States (CIS), and Latin America. The Emerging Markets division contributes approximately 18 per cent to Sun Pharma’s global revenue.

In addition to leading the Emerging Markets segment, Shanghvi later took on responsibilities in Global Generic R&D, Global Business Development (Generics), Operations, and Active Pharmaceutical Ingredients (API). Since June 2023, he has been serving as a Whole-time Director at Sun Pharma.

Shanghvi holds a degree in Cellular and Molecular Biology from the University of Michigan – Ann Arbor.

Related Posts

  • Pharma
  • February 17, 2025
  • 59 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 61 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%